Literature DB >> 11374329

Treatment regimen and hypnotic self-administration.

T Roehrs1, A Bonahoom, B Pedrosi, L Rosenthal, T Roth.   

Abstract

RATIONALE AND
OBJECTIVES: Previous studies have shown that insomniacs self-administer hypnotics at high nightly rates. This study determined whether prior experience with different treatment regimens (i.e., instructions and capsule availability) would alter the previously observed high hypnotic self-administration rates.
METHODS: Sixty-four healthy men and women with (n = 32) and without (n = 32) insomnia, 21-55 years, self administered placebo or triazolam (0.25 mg) after different prior treatment regimens. They received one of three different treatment regimens enforced for 11 nights: a capsule each night, a capsule as needed, or a capsule every third night. On 14 subsequent nights they choose to self-administer a capsule or not, placebo during 1 week and triazolam (0.25 mg) the other (counterbalanced in order).
RESULTS: Insomniacs self-administered more capsules than normals and triazolam was self-administered more than placebo. For both groups, treatment regimen had a minimal effect on capsule self-administration. During the treatment phase, triazolam improved self-ratings of sleep relative to placebo. During the choice phase, nightly variations in self-rated sleep predicted self-administration of a capsule on the following night, regardless of whether the capsule was active drug or placebo.
CONCLUSIONS: The data of this study are consistent with the view that hypnotic self-administration by insomniacs is therapy-seeking behavior and not drug abuse.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11374329     DOI: 10.1007/s002130000661

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  6 in total

Review 1.  Hypnotics: an update.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

2.  The health effects of at-home written emotional disclosure in fibromyalgia: a randomized trial.

Authors:  Mazy E Gillis; Mark A Lumley; Angelia Mosley-Williams; James C C Leisen; Timothy Roehrs
Journal:  Ann Behav Med       Date:  2006-10

Review 3.  Insomnia pharmacotherapy.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

4.  Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.

Authors:  Michael J Sateia; Daniel J Buysse; Andrew D Krystal; David N Neubauer; Jonathan L Heald
Journal:  J Clin Sleep Med       Date:  2017-02-15       Impact factor: 4.062

5.  Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.

Authors:  Thomas Roth; Steven G Hull; D Alan Lankford; Russell Rosenberg; Martin B Scharf
Journal:  Sleep       Date:  2008-09       Impact factor: 5.849

6.  Efficacy and safety of as-needed, post bedtime dosing with indiplon in insomnia patients with chronic difficulty maintaining sleep.

Authors:  Thomas Roth; Gary K Zammit; Martin B Scharf; Robert Farber
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.